Medicine
MD Gastroview 600 mg/100 mg per mL oral solution
MD Gastroview 600 mg/100 mg per mL oral solution is a prescription medicine containing Diatrizoate for oral, rectal use, marketed by Liebel-Flarsheim, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), Avoid excessive heat. If precipitation or…
Key facts
- Active ingredient (INN)
- Diatrizoate
- Brand
- MD Gastroview
- Strength
- 600 mg/100 mg per mL
- Dosage form
- Oral solution
- Route
- Oral, rectal
- Packs
- 25 bottles
- Marketing authorisation holder
- Liebel-Flarsheim
- Manufacturer
- Liebel-Flarsheim
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), Avoid excessive heat. If precipitation or solidification has occurred due to storage in the cold, the bottle should be brought to room temperature. Storage Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V08AA01 Diatrizoate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 August 2009
- Identifiers
- DailyMed set ID b348b1cf-6250-4ab6-b2bf-3bff86628c53NDC 0019-4816Application ANDA087388
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 bottle, glass in 1 box / 30 mL in 1 bottle, glass | 0019-4816-04 | Liebel-Flarsheim | 31 August 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 November 1954 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Diatrizoate
Clinical summary
Diatrizoate is a radiographic contrast agent indicated for retrograde cystourethrography. It is available as oral solution, injection and oral liquid for rectal and intravenous use. MedsAcross supplies Diatrizoate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DiatrizoateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cystografin prescribing information (Bracco Diagnostics) · U.S. National Library of Medicine, DailyMed
Need MD Gastroview 600 mg/100 mg per mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.